ALLIED INNOVATIVE SYSTEMS — Department of Health and Human Services SBIR Phase II: NHLBI

Description

DESCRIPTION provided by applicant The long term goal of the proposed research is to develop a novel quantitative particle agglutination technology for improving the performance of blood typing assays The conventional hemagglutination blood typing assays have serious drawbacks such as limited sensitivity long time of incubation subjectivity and large amount of reagents It is in this context that we propose to develop a new technology which is free from the aforementioned limitations of the conventional hemagglutination assays The proposed immunoassay is a sensitive and rapid method that utilizes inexpensive instrumentation The Specific Aims of Phase II are To further explore all variables affecting the performance of the new blood typing detection assays and optimize the performance of the assay To design and assemble an rototype of the device for performing of several blood typing assays simultaneously The rototype is intended to test the design of every technical element of the system before it is implemented in the final pre production prototype To validate the detection assays for determination of blood groups including weak D group and C c E e and K antigens and expected antibodies reverse typing To examine a statistically significant number of clinical samples for each assay and carry out statistical analysis and demonstrate reproducibility of the obtained results To compare performance of the conventional and newly developed assays Significantly the new method presents a general approach for enhancement and detection of agglutination of particles of different origin including latex silic microparticles and biological cells PUBLIC HEALTH RELEVANCE The development of this method will allow one to obtain quantitative results increase the sensitivity of red blood cell agglutination assays and reduce time of analysis without compromising the cost per test Successful completion of these studies will result in a substantial business opportunity to license the technology and manufacture commercial products which will be beneficial for public health